Jon Congleton

Jon Congleton is a declared insider of Mineralys Therapeutics, Inc. (chief executive), with filings sourced from SEC (Form 4). Between 11 August 2023 and 30 September 2026, the trades on record add up to 22 filings.

Both buying and selling appear: 4 purchases worth €97k, against 16 sales worth €5.2M. The amount is not disclosed for 2 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 1 share grant and 1 option exercise. Since January 2026: no purchases and 7 sales on the market.

Half of the purchases are above €24k and half below. Across 4 purchases, this insider has always bought alone, with no colleague buying within 30 days. For 4 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 25% of cases, with a median move of -36.9%. These figures describe past trades and do not predict future prices.

The newest entry dates from 2 October 2026: an open-market sale of €1.7M, in Mineralys Therapeutics, Inc. The latest purchase dates back some time: it was published 1,056 days ago, on 27 November 2023. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.